318 related articles for article (PubMed ID: 16520985)
1. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
3. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
4. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
6. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
7. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
8. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
10. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
[TBL] [Abstract][Full Text] [Related]
11. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Bessho Y; Oguri T; Achiwa H; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Cancer Sci; 2006 Mar; 97(3):192-8. PubMed ID: 16542215
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Katayama K; Shibata K; Mitsuhashi J; Noguchi K; Sugimoto Y
Anticancer Res; 2009 Apr; 29(4):1059-65. PubMed ID: 19414346
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells.
Nakano H; Nakamura Y; Soda H; Kamikatahira M; Uchida K; Takasu M; Kitazaki T; Yamaguchi H; Nakatomi K; Yanagihara K; Kohno S; Tsukamoto K
Cancer; 2008 Mar; 112(5):1122-30. PubMed ID: 18219662
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
16. Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Ohtsuka K; Ohnishi H; Morii T; Fujiwara M; Kishino T; Ogura W; Chiba M; Matsushima S; Goya T; Watanabe T
J Thorac Oncol; 2010 Nov; 5(11):1726-33. PubMed ID: 20975373
[TBL] [Abstract][Full Text] [Related]
17. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
[TBL] [Abstract][Full Text] [Related]
19. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
[TBL] [Abstract][Full Text] [Related]
20. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
